IDEXX Laboratories, Inc.
IDXX
$550.82
-2.82%
IDEXX Laboratories, Inc. is a global leader in the veterinary diagnostics and software industry, primarily developing, manufacturing, and distributing diagnostic products, equipment, and services for companion animals and livestock. The company holds a dominant market position as a vertically integrated platform provider, offering a comprehensive ecosystem of in-clinic analyzers, rapid test kits, reference laboratory services, and practice management software that creates high customer switching costs. The current investor narrative is focused on the company's resilient demand profile, as evidenced by its recent guidance raise driven by higher clinical visits and diagnostic frequency, which underscores the defensive growth characteristics of the pet healthcare sector despite broader economic uncertainties.…
IDXX
IDEXX Laboratories, Inc.
$550.82
Related headlines
Investment Opinion: Should I buy IDXX Today?
Rating & Thesis: Hold. IDXX is a high-quality company caught in a valuation repricing; investors should wait for either a more attractive entry point or clearer signs of growth re-acceleration before committing new capital. This aligns with the mixed analyst sentiment, which includes both 'Buy' and 'Neutral' ratings, and the stock's position near 52-week lows suggests the market is still digesting these risks.
Supporting Evidence: The stock trades at a forward P/E of 34.12x, a significant premium to sector peers, while revenue growth has decelerated sequentially to 14.28% YoY. Profitability remains a standout strength with a 60.35% gross margin and 31.6% operating margin, and free cash flow generation is robust at $1.05 billion TTM. However, the technical picture is severely damaged, with the stock down 25% over six months and showing persistent relative weakness (underperforming SPY by 24.5% over three months). The implied upside to the average analyst target is not provided in the data, but the stock's proximity to its 52-week low suggests limited near-term catalyst for a major rebound.
Risks & Conditions: The two biggest risks are 1) further growth deceleration pressuring the premium multiple, and 2) continued market volatility disproportionately impacting this high-beta stock. This Hold rating would upgrade to a Buy if the forward P/E compressed toward 25-28x (offering a larger margin of safety) or if quarterly revenue growth re-accelerates back above 16% YoY. It would downgrade to a Sell if revenue growth falls below 10% or if the stock decisively breaks below its 52-week low of $504.56 on high volume. Based on current data, the stock appears fairly valued to slightly overvalued relative to its near-term growth trajectory but undervalued relative to its long-term quality characteristics.
Sign up to view all
IDXX 12-Month Price Forecast
IDXX is a classic 'good company, bad stock' scenario in the near term. Its underlying business is robust, cash-generative, and operates in a defensive sector, but the stock is undergoing a painful valuation correction after years of premium pricing. The base case (55% probability) of range-bound trading between $580-$650 is most likely, as the market digests decelerating growth against still-strong fundamentals. The stance would turn bullish on a confirmed technical reversal above $650 coupled with evidence of growth stabilization; it would turn bearish on a breakdown below the $504 support with volume, signaling a failed consolidation and further de-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $716.07 and implied upside of +30.0% versus the current price.
Average Target
$716.07
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$441 - $716
Analyst target range
Analyst coverage appears limited with only 5 analysts providing estimates, indicating this large-cap stock may have concentrated or specialized coverage. The consensus sentiment leans bullish, as evidenced by recent institutional ratings which include actions like 'Buy' from Stifel and 'Overweight' from Barclays and JP Morgan, though 'Neutral' ratings from UBS and Piper Sandler suggest some caution. The average revenue estimate for the forward period is $6.98 billion, with a tight range from a low of $6.88 billion to a high of $7.04 billion, signaling strong conviction in the company's near-term financial trajectory despite the wide target price spread that often accompanies high-growth, high-multiple stocks.
Bulls vs Bears: IDXX Investment Factors
The bull case is anchored in IDXX's defensive, high-quality fundamentals: robust double-digit revenue growth, exceptional 60%+ gross margins, and powerful free cash flow generation in a resilient end-market. The bear case is driven by a severe technical breakdown, a still-lofty valuation premium, and signs of sequential growth deceleration. Currently, the bearish technical and valuation arguments hold stronger evidence, as the stock's 25% six-month decline and persistent underperformance reflect a market repricing of growth expectations. The single most important tension in the investment debate is whether the company's decelerating but still-strong 14% revenue growth can sustainably support a forward P/E multiple of 34x, which is a significant premium to the sector, especially if macroeconomic pressures intensify.
Bullish
- Resilient Double-Digit Revenue Growth: Q4 2025 revenue grew 14.28% YoY to $1.09B, driven by higher clinical visits and diagnostic frequency. This underscores the defensive, non-cyclical nature of the pet healthcare sector, providing a stable growth foundation.
- Exceptional Profitability & Pricing Power: The company maintains a gross margin of 60.35% and an operating margin of 31.6%, demonstrating significant pricing power and operational efficiency. A Return on Equity of 66.0% is exceptionally high, indicating superior capital allocation.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $1.05 billion, providing ample internal resources for reinvestment and shareholder returns. This robust cash generation supports the premium valuation and provides a margin of safety.
- Raised Guidance Signals Confidence: Recent news indicates the company raised its long-term guidance based on higher clinical visits and diagnostic frequency. This management confidence acts as a positive fundamental catalyst, reinforcing the resilient demand narrative.
Bearish
- Severe Technical Downtrend & Weakness: IDXX is in a pronounced downtrend, down 25.15% over six months and underperforming the SPY by 35.85 percentage points in that period. Trading near 52-week lows suggests persistent selling pressure and broken investor sentiment.
- Elevated Valuation Despite Correction: Even after the sell-off, the forward P/E of 34.12x and P/S of 12.6x represent a substantial premium to typical healthcare diagnostics peers. A PEG ratio of 2.3 suggests growth is already priced in, leaving little room for error.
- Revenue Growth Sequentially Decelerating: Q4 2025 revenue growth of 14.28% YoY marks a deceleration from 15.8% in Q3 and 16.7% in Q2 2025. This trend, if it continues, could challenge the high-growth narrative that justifies the premium multiple.
- High Beta Amplifies Market Volatility: With a beta of 1.574, IDXX is approximately 57% more volatile than the broader market. In a risk-off environment, this high beta exacerbates downside moves, as seen in its severe underperformance versus the SPY.
IDXX Technical Analysis
The stock is in a pronounced downtrend, having declined 25.15% over the past six months and currently trading near the lower end of its 52-week range. With a current price of $563.53, it sits just 11.7% above its 52-week low of $504.56 and 26.8% below its 52-week high of $769.98, indicating significant technical damage and positioning the stock as a potential value opportunity, albeit one that could still be a 'falling knife.' Recent momentum shows a stark divergence from the broader market, with IDXX up only 1.78% over the past month while the SPY gained 6.31%, and down 14.19% over three months versus the SPY's 10.28% gain, highlighting severe relative weakness. The stock's high beta of 1.574 confirms it is approximately 57% more volatile than the market, which amplifies both downside and potential upside moves, making risk management critical. Key technical support is clearly defined at the 52-week low of $504.56, while resistance lies at the recent highs near the $650 area; a decisive break below support could trigger another leg down, whereas a reclaim of the $600-$620 zone would be the first sign of stabilization.
Beta
1.57
1.57x market volatility
Max Drawdown
-31.0%
Largest decline past year
52-Week Range
$507-$770
Price range past year
Annual Return
+7.0%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -2.9% | +5.4% |
| 3m | -15.1% | +10.9% |
| 6m | -23.2% | +11.0% |
| 1y | +7.0% | +28.1% |
| ytd | -17.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
Revenue growth remains robust but has shown sequential deceleration; the most recent Q4 2025 revenue was $1.09 billion, representing a solid 14.28% year-over-year increase, though this marks a slowdown from the 15.8% growth in Q3 and 16.7% in Q2 of 2025. The business is split between Product revenue ($652.4 million) and Service revenue ($438.1 million), with both segments contributing to the overall expansion driven by higher diagnostic utilization. Profitability is exceptionally strong, with the company reporting net income of $248.2 million in Q4 and maintaining a high gross margin of 60.35%, which has been stable around the 61-62% range throughout 2025, demonstrating pricing power and operational efficiency in a premium industry. The balance sheet and cash flow are healthy, with a manageable debt-to-equity ratio of 0.67, a robust return on equity of 65.99%, and substantial free cash flow generation, evidenced by a trailing twelve-month FCF of $1.05 billion, providing ample internal resources for growth investments and shareholder returns via share repurchases.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given the company's substantial profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 51.15x, while the forward PE is notably lower at 34.12x, indicating the market expects significant earnings growth to justify the current price. Compared to sector averages, IDXX's valuation represents a substantial premium; for instance, its forward PE of 34.12x is significantly above typical healthcare diagnostics peers, which often trade in the low-to-mid 20s, a premium justified by its market-leading position, high margins, and consistent double-digit growth profile. Historically, the current trailing PE of 51.15x is below the stock's own extreme highs seen in 2021-2022 (reaching above 85x) but remains above its longer-term median, suggesting expectations, while tempered from peak optimism, still price in a high-quality, growth compounder.
PE
51.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 35x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IDXX's primary financial risk is its premium valuation, which depends entirely on sustaining high growth rates. The forward P/E of 34.12x and P/S of 12.6x are significantly above sector averages, making the stock vulnerable to multiple compression if revenue growth decelerates further from the current 14.28% YoY pace. While the balance sheet is healthy with a Debt-to-Equity of 0.67 and profitability is strong, the high ROE of 66% may be difficult to maintain as the company scales, posing a risk to its premium pricing. Revenue concentration, while not extreme, is tied to the cyclicality of companion animal veterinary visits, which could soften in a deep economic downturn despite the sector's historical resilience.
Market & Competitive Risks: The stock faces significant market risk from its high beta of 1.57, meaning it is 57% more volatile than the market and prone to amplified sell-offs during risk-off periods, as evidenced by its 35.8 percentage point underperformance versus the SPY over the past six months. Competitive risks, while mitigated by high customer switching costs in its vertically integrated platform, include potential price competition and technological disruption. The substantial valuation premium (forward PE ~34x vs. peers in low 20s) creates a high hurdle; any disappointment in earnings or a sector-wide de-rating of growth stocks could trigger a sharp re-rating downward toward peer multiples.
Worst-Case Scenario: The worst-case scenario involves a combination of a deeper economic recession reducing discretionary pet healthcare spending, a faster-than-expected deceleration in revenue growth to single digits, and a concurrent compression of its valuation multiple toward the sector average. This could trigger a cascade of analyst downgrades and institutional selling. A realistic downside target aligns with the 52-week low of $504.56, representing a further -10.5% decline from the current price of $563.53. In a more severe bear case where growth stalls and multiples contract sharply, a drop to the $450-$475 range (a 20-25% decline) is plausible, mirroring the stock's historical max drawdown of -31%.
FAQ
The key risks are: 1) Valuation Compression: The stock's high forward P/E (34x) is vulnerable if growth decelerates or market sentiment sours on premium-priced growth stocks. 2) Growth Slowdown: Revenue growth has sequentially decelerated from 16.7% to 14.28% YoY; a further slowdown would severely pressure the stock. 3) High Volatility: With a beta of 1.57, IDXX is 57% more volatile than the market, amplifying losses during downturns, as seen in its 35.8% underperformance vs. the SPY over six months. 4) Economic Sensitivity: While pet healthcare is defensive, a deep recession could impact discretionary spending on advanced veterinary diagnostics, affecting the top line.
Our 12-month outlook presents three scenarios. The Base Case (55% probability) sees the stock consolidating between $580 and $650 as growth stabilizes and the current ~34x forward P/E holds. The Bull Case (25% probability) targets $700-$770, requiring growth re-acceleration and multiple expansion. The Bear Case (20% probability) targets a retest of the 52-week low at $504, potentially going lower, driven by growth disappointment and multiple compression. The Base Case is most likely, implying limited near-term upside from the current ~$563 price but also defining clear downside support. The key assumption is that revenue growth stabilizes in the low-to-mid teens.
IDXX stock is fairly valued to slightly overvalued based on near-term metrics, but its premium is justified by long-term quality. Its forward P/E of 34.12x and Price/Sales of 12.6x are significantly above sector averages for diagnostics, indicating a substantial premium. This premium is supported by superior profitability (60% gross margin, 66% ROE) and resilient double-digit growth. However, the sequential deceleration in revenue growth (from 16.7% to 14.28% YoY) challenges whether the current multiple is sustainable. Relative to its own history, the trailing P/E of 51x is below past peaks but still elevated, suggesting the market is pricing in a high-quality compounder, leaving little room for error.
IDXX is a high-quality company, but it is not an unequivocally good buy at the current moment. The stock has declined 25% in six months and trades near its 52-week low, which improves the risk/reward profile. However, with a forward P/E of 34x and revenue growth showing signs of deceleration, the valuation still demands near-perfect execution. It could be a good buy for patient, long-term investors who believe in the secular pet care trend and are willing to average in on weakness, but short-term traders should be wary of the high beta (1.57) and ongoing technical downtrend.
IDXX is primarily suitable for long-term investors with a minimum 3-5 year horizon. The company's competitive moat, high customer switching costs, and exposure to the secular growth of pet healthcare are long-duration themes. The stock's high beta and volatility make it a poor candidate for short-term trading. Furthermore, the lack of a dividend means total return is dependent entirely on capital appreciation, which requires time for the underlying business growth to overcome near-term valuation pressures. Investors should be prepared for significant price swings but can hold through them based on the company's fundamental quality.